Merck & Co., Inc. $MRK Stock Holdings Reduced by Investment House LLC

Investment House LLC decreased its holdings in Merck & Co., Inc. (NYSE:MRK) by 47.0% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 29,177 shares of the company’s stock after selling 25,843 shares during the quarter. Investment House LLC’s holdings in Merck & Co., Inc. were worth $4,240,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. Bullseye Investment Management LLC purchased a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at about $27,000. Horizons Wealth Management acquired a new position in Merck & Co., Inc. in the 3rd quarter valued at about $30,000. Graney & King LLC raised its stake in shares of Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the last quarter. Montgomery Financial Services LLC acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter worth $41,000. Finally, Evergreen Advisors LLC purchased a new stake in shares of Merck & Co., Inc. in the first quarter valued at approximately $43,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported Phase 3 INTerpath-001 results showing that intismeran autogene combined with KEYTRUDA reduced the risk of melanoma recurrence or death by 42%, while also improving distant metastasis-free survival. The data met market expectations and could support a future expansion of Merck’s oncology pipeline beyond KEYTRUDA. Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
• Positive Sentiment: The European Commission approved KEYTRUDA plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer. The wider label expands the addressable market for Merck’s leading oncology franchise and may help offset future pressure from slowing KEYTRUDA growth. European Commission approves KEYTRUDA plus Padcev
• Neutral Sentiment: Trading activity included approximately 37,444 MRK call options, about 40% above average daily volume, indicating increased speculative interest but not establishing a clear direction for the shares.
• Negative Sentiment: An apparent early leak of the melanoma-vaccine data caused volatility and appears to have prompted profit-taking. Investors may have expected a larger-than-reported benefit despite the statistically and clinically positive results, creating a sell-the-news response ahead of the formal ESMO presentation. Moderna, Merck shares fall after possible melanoma data leak
• Negative Sentiment: Analysts expect Merck’s upcoming third-quarter earnings to decline, limiting near-term enthusiasm and reinforcing concerns about moderating KEYTRUDA growth. Zacks also reportedly downgraded MRK from “hold” to “strong sell,” adding pressure to sentiment.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares in the company, valued at $2,344,248.64. This trade represents a 50.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 228,238 shares of company stock worth $29,977,783 over the last 90 days. 0.17% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Wolfe Research upped their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research note on Tuesday, August 25th. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research report on Wednesday, August 12th. Argus raised their price target on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Rothschild & Co Redburn lifted their price target on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a report on Monday, July 6th. Finally, Morgan Stanley dropped their price objective on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research note on Wednesday, October 7th. Seventeen research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $151.92.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $147.40 on Friday. The stock’s 50-day moving average is $146.79 and its 200-day moving average is $130.07. The company has a market cap of $363.67 billion, a price-to-earnings ratio of 117.92, a price-to-earnings-growth ratio of 6.92 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. Merck & Co., Inc. has a 12 month low of $82.01 and a 12 month high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the previous year, the company posted $2.13 EPS. The company’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 2.66 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.